Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by lscfaon Jan 16, 2023 6:36pm
81 Views
Post# 35226729

RE:Dividend On Preferred Shares

RE:Dividend On Preferred Shares

WTF? The annual dividend is only $30,495..... Last year the $30,495 div was settled for $47,737 in shares. 



Ingiboy wrote: This announced today by Replicel:

REPLICEL LIFE SCIENCES ANNOUNCES INTENTION TO PAY DIVIDEND ON PREFERRED SHARES

RepliCel Life Sciences Inc. intends to pay accrued dividends of $53,367.13 outstanding on the Class A preferred shares in 508,253 common shares of the company at a price of 10.5 cents per share. 

The proposed dividend payment is subject to the approval of the TSX Venture Exchange. 

All securities issued in connection with the dividend payment will be subject to a statutory hold period expiring four months and one day after issuance of the securities. 

David Hall, Peter Lewis and Andrew Schutte are among the 16 investors who participated in the 2019 private placement of Class A preferred shares -- all of whom will be receiving a dividend payment. These three are each considered to be a related party within the meaning of Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions, and each issuance is considered to be a related party transaction within the meaning of MI 61-101, but each issuance will be exempt from the valuation requirement of MI 61-101 by virtue of the exemption contained in Section 5.5(b) as the company's shares are not listed on a specified market and from the minority shareholder approval requirements of MI 61-101 by virtue of the exemption contained in Section 5.7(a) of MI 61-101 in that the fair market value of the consideration of the shares to be issued to each related party does not exceed 25 per cent of the company's market capitalization.

For a company on life support financially this boggles the mind.




 

<< Previous
Bullboard Posts
Next >>